Cervical cancer kills one Indian woman every five minutes.
That single fact is the most powerful argument for HPV vaccination in Chennai and across India. Because cervical cancer is not simply treatable. It is largely preventable. The human papillomavirus (HPV) is responsible for approximately 70 % of all cervical cancer cases worldwide, and HPV types 16 and 18 alone cause 82% of cervical cancers in India. A vaccine that protects against these strains can, when given at the right time, prevent the vast majority of those deaths.
India took its strongest step yet toward this goal on 28 February 2026, when Prime Minister Modi launched a nationwide HPV vaccination drive for 14-year-old girls, building on the NTAGI recommendation to include HPV vaccination in the Universal Immunization Programme.
But national programmes reach only a specific age group at a specific time. The full picture of HPV vaccination in Chennai for families is broader, and more important, than many parents know. This guide answers the questions every family should have the answers to.
What Is HPV and Why Does It Matter?
Human papillomavirus is a family of over 200 related viruses. It is transmitted primarily through skin-to-skin intimate contact, including sexual contact, and is extraordinarily common. Most sexually active men and women contract at least one type of HPV at some point in their lives, often within months to years of becoming sexually active. Most infections clear on their own without symptoms. But not all.
The high-risk strains of HPV, particularly HPV 16 and HPV 18, can establish persistent infections that over years to decades cause cellular changes leading to cancer. HPV is responsible for:
-
Cervical cancer (approximately 99.7% of cases caused by HPV)
-
Vaginal cancer
-
Vulvar cancer
-
Anal cancer (in both women and men)
-
Penile cancer
-
Oropharyngeal cancers (throat and base of tongue, now the most rapidly increasing HPV-related cancer in many countries)
-
Genital warts (caused by low-risk strains HPV 6 and 11)
The critical insight for families is that HPV is not only a women's health issue. Men are infected by HPV, transmit it to partners, and are themselves at risk of HPV-related cancers. This is why the Indian Academy of Paediatrics now recommends HPV vaccination for all children, boys and girls, from age 9.
At any given time, 6.6% of women in the general population in India have cervical HPV infections, and nearly 80% of sexually active women are likely to contract genital HPV by age 50. In Chennai and across Tamil Nadu, where cervical cancer remains a leading cause of cancer mortality in women, the public health case for family-wide HPV vaccination is direct and urgent.
How Does the HPV Vaccine Work?
HPV vaccines are prophylactic. They prevent infection with the HPV strains they target. They do not treat an existing HPV infection and do not reverse HPV-related cell changes that have already occurred.
This is the most important concept for parents to understand, and the one that most directly determines when the vaccine should be given.
The vaccines work by stimulating the immune system to produce antibodies against specific HPV proteins. When the vaccinated person subsequently encounters the HPV virus, the immune system recognises and eliminates it before it can establish an infection. The antibody response produced by the vaccine is significantly stronger than the natural immune response to infection, providing more durable protection.
Two doses given 6 months apart in children aged 9 to 14 produce higher antibody levels than three doses in older teenagers and adults. The immune system's response to the vaccine is strongest in the years just before sexual debut, making the pre-adolescent years the optimal window for vaccination.
IAP 2025 data suggests a single dose may be sufficient for immunocompetent girls aged 9 to 15, though the standard two-dose schedule remains the recommended approach while evidence for single-dose protection accumulates.
Which HPV Vaccines Are Available in Chennai?
Three HPV vaccines are currently available in India, each offering different levels of protection.
Cervavac (Serum Institute of India)
Cervavac is India's own quadrivalent HPV vaccine, developed by the Serum Institute of India in coordination with the Department of Biotechnology, Government of India. It received WHO prequalification in 2024, confirming it meets international manufacturing, safety, and efficacy standards.
Cervavac targets four HPV strains:
-
HPV 6 and 11 (responsible for approximately 90% of genital warts)
-
HPV 16 and 18 (responsible for approximately 70 to 82% of cervical cancers in India)
Cost in the private market: approximately Rs 2,000 per dose. Under the national immunisation programme, it is offered free of charge to girls aged 9 to 14 at government health centres.
Cervavac has made HPV vaccination significantly more affordable for Indian families than was previously possible with imported vaccines alone.
Gardasil (Quadrivalent)
Gardasil is the imported quadrivalent HPV vaccine from MSD (Merck). It targets the same four HPV strains as Cervavac (6, 11, 16, 18). Cost in Chennai: approximately Rs 3,000 to 4,000 per dose.
Gardasil 9 (Nonavalent)
Gardasil 9 is the most comprehensive HPV vaccine available, protecting against nine HPV strains:
- HPV 6, 11 (genital warts)
- HPV 16, 18 (highest risk cervical and oropharyngeal cancer strains)
- HPV 31, 33, 45, 52, 58 (five additional high-risk strains accounting for a further approximately 15 to 20% of cervical cancers)
Gardasil 9 provides approximately 90% protection against HPV-related cancers overall, compared to approximately 70 to 82% for the quadrivalent vaccines. It is the broadest-protection HPV vaccine currently available anywhere.
Cost in Chennai: approximately Rs 9,000 to 10,850 per dose. Three doses are required for most recipients, making total cost a significant consideration in the choice between quadrivalent and nonavalent vaccines.
The recommendation choice between Cervavac or Gardasil and Gardasil 9 should be discussed with a paediatrician or gynaecologist, taking into account the child's age, the family's budget, and the degree of protection desired.
Who Should Get HPV Vaccination in Chennai?
While often thought of only as a cervical cancer shot for young girls, the HPV vaccine protects both women and men against multiple cancers and viral infections across different stages of life. Determining the right time to get vaccinated comes down to age, immune response, and prior exposure, ensuring maximum protection for the long term.
Girls and Boys Aged 9 to 14: The Priority Group
The Indian Academy of Paediatrics recommends HPV vaccination for all children, both boys and girls, starting at age 9. The ideal window is 9 to 14 years.
Why this age group is the highest priority:
-
The immune response to the vaccine is strongest before sexual debut
-
Two doses (rather than three) are sufficient, reducing cost and visits
-
The antibody levels generated in this age group are higher than in older recipients, providing better long-term protection
-
Two doses six months apart in this age group provide over 97% protection against HPV 16 and 18
The 2026 national programme targets 14-year-old girls specifically, but the private-sector recommendation extends to all children from age 9. Boys in this age group receive equal benefit from the vaccine and should be vaccinated alongside their sisters.
Girls and Young Women Aged 15 to 26: Catch-Up Vaccination
Young women who were not vaccinated between ages 9 and 14 should receive catch-up vaccination as soon as possible. From age 15 onward, three doses are required, given at 0, 2, and 6 months.
The vaccine is most effective when given before any HPV exposure, but many women in this age group who have had some sexual activity will not have been exposed to all the HPV strains targeted by the vaccine. Vaccination still provides meaningful protection against the strains not yet encountered.
Routine catch-up vaccination is recommended up to age 26 without requiring a discussion of prior sexual history. Every young woman aged 15 to 26 who has not been vaccinated should be offered HPV vaccination at the next clinical opportunity.
Women Aged 27 to 45: Shared Clinical Decision
The HPV vaccine is licensed in India up to age 45. After age 26, the benefit decreases progressively because prior HPV exposure becomes more likely with each passing year, and the vaccine cannot provide protection against strains to which the person has already been exposed.
However, a woman who has not been vaccinated and has not been exposed to all vaccine-targeted HPV strains still receives partial protection from vaccination. After 26, the benefit is lower because prior HPV exposure becomes more likely, but it is still worth discussing with your gynaecologist if you have not been vaccinated before.
Women aged 27 to 45 who have had limited sexual partners, who are in a new relationship, or who for other clinical reasons have a lower probability of prior HPV exposure across all vaccine-targeted strains, may receive meaningful benefit from vaccination. This is a shared decision-making discussion with a gynaecologist.
Boys and Men Aged 9 to 26: An Underappreciated Group
The case for HPV vaccination in boys is now well-established and endorsed by the IAP. Boys who receive the HPV vaccine are protected against:
-
Genital warts (HPV 6 and 11)
-
Penile cancer
-
Anal cancer
-
Oropharyngeal cancer, which is the most rapidly growing HPV-related cancer and predominantly affects men
Additionally, vaccinated boys cannot transmit the vaccine-targeted HPV strains to their future partners, providing indirect community protection (herd immunity) that reduces the overall burden of HPV-related disease in the population. The national programme currently targets girls, but comprehensive family-level HPV vaccination includes boys, and many urban families in Chennai are choosing to vaccinate sons alongside daughters.
Immunocompromised Individuals
People with immunocompromising conditions including HIV infection, post-transplant immunosuppression, or those on immunosuppressive medications for autoimmune conditions should receive HPV vaccination. Three doses are required regardless of age. Immunocompromised individuals are at higher risk of persistent HPV infection and HPV-related disease, making vaccination particularly important for this group.
HPV Vaccine Schedule in India: A Clear Summary
The schedule depends on the age at first vaccination:
Ages 9 to 14:
-
Two doses: dose 1 at month 0, dose 2 at month 6
-
The second dose can be given anywhere from 5 to 12 months after the first
-
Provides high-level protection with over 97% efficacy against HPV 16 and 18
Ages 15 and above:
-
Three doses: 0, 2, and 6 months for Cervavac and Gardasil; 0, 2, and 6 months for Gardasil 9
-
All three doses should be completed within 12 months
Immunocompromised individuals (any age):
- Three doses regardless of age at first vaccination
Pregnancy:
-
The HPV vaccine is not recommended during pregnancy
-
Vaccination should be deferred until after delivery
-
If vaccination is started before pregnancy is discovered, the remaining doses should be given after delivery
Common Myths About HPV Vaccination That Prevent Uptake
India's HPV vaccination coverage has been held back by persistent myths that are not supported by the medical evidence. Addressing these directly helps families make genuinely informed decisions.
-
Myth: The HPV vaccine encourages sexual activity in girls Evidence: Multiple large studies across multiple countries have consistently found no change in sexual behaviour following HPV vaccination. The vaccine prevents cancer, not relationships.
-
Myth: My daughter is too young for this vaccine Evidence: The vaccine is most effective when given before any HPV exposure. Age 9 to 14 produces the highest antibody response and requires only two doses. Waiting until adulthood means three doses are needed, cost is higher, and prior exposure may have already reduced the benefit.
-
Myth: Boys do not need the HPV vaccine Evidence: HPV causes cancers in men including penile, anal, and oropharyngeal cancers. HPV is responsible for approximately 70% of oropharyngeal cancers, which are increasingly common in men. The IAP recommends vaccination for all children, boys and girls, from age 9. Vaccinating boys also protects their future partners.
-
Myth: My child has already had the chicken pox vaccine, so the HPV vaccine is covered Evidence: HPV vaccination is completely separate from all other childhood vaccinations. It protects against a specific cancer-causing virus that no other childhood vaccine addresses.
-
Myth: The HPV vaccine is not safe Evidence: HPV vaccines are among the most extensively studied vaccines in history. They have been administered to hundreds of millions of people globally. Major adverse effects are rare and well-characterised. The most common reactions are mild local reactions at the injection site and brief fainting in adolescents (vasovagal response), which is managed by asking the recipient to sit for 15 minutes after injection.
-
Myth: Once vaccinated, cervical screening (Pap smear) is no longer needed Evidence: The HPV vaccine does not protect against all HPV strains. Regular cervical screening (Pap smear or HPV DNA test) remains essential for vaccinated women, beginning from age 21 to 25 or three years after sexual debut, whichever comes first.
HPV Vaccination and Cervical Screening: A Two-Part Prevention Strategy
The HPV vaccine and regular cervical screening are complementary, not alternative, cancer prevention tools.
HPV vaccination prevents infection with the strains most likely to cause cervical cancer. Cervical screening detects precancerous changes early, when they are treatable, for the minority of cases where either vaccine-targeted or non-targeted strains cause cell changes despite vaccination.
The current cervical cancer screening recommendation for Indian women:
-
Begin Pap smear (cervical cytology) from age 21 to 25 or three years after first sexual contact, whichever comes first
-
Every three years if the result is normal
-
HPV DNA testing is now preferred over Pap smear in many countries and is increasingly available in Chennai's private healthcare sector, providing better sensitivity for detecting high-risk HPV strains before cell changes occur
Combining vaccination in the pre-adolescent years with regular screening from young adulthood offers the most complete cervical cancer prevention available.
What to Expect at an HPV Vaccination Appointment
An HPV vaccination appointment at a private clinic includes a brief consultation confirming eligibility, a discussion of the vaccine options and schedule, and administration of the vaccine.
Practical points:
-
The vaccine is given as an intramuscular injection, typically in the upper arm
-
The recipient should sit or lie down for 15 minutes after injection to prevent vasovagal (fainting) reactions
-
Mild pain, redness, and swelling at the injection site are common in the 24 to 48 hours after vaccination and resolve spontaneously
-
Fever and headache are less common reactions
-
No fasting is required before vaccination
-
Bring previous vaccination records to the appointment
Documentation: A vaccination record is issued after each dose. This should be kept safely and brought to subsequent doses. In the future, this record confirms vaccination status for employers, travel, and healthcare providers.
HPV Vaccination at Humayun Hospital, T Nagar
At Humayun Hospital, T Nagar, Chennai, our paediatric and gynaecology team provides HPV vaccination consultations and vaccine administration for children, adolescents, and adults across the full eligible age range. We offer:
-
Consultation to determine the appropriate vaccine (Cervavac, Gardasil, or Gardasil 9) based on age, health status, and protection goals
-
Vaccination for girls and boys from age 9 onward
-
Catch-up vaccination for young women aged 15 to 26
-
Shared decision-making consultations for women aged 27 to 45
-
Vaccination for immunocompromised individuals with appropriate scheduling
-
Complete vaccination schedule management across all required doses
-
Cervical cancer screening advice alongside vaccination, ensuring that Pap smear or HPV DNA testing is appropriately scheduled for vaccinated women as they reach screening age
-
Dr. Asma Humayun, MRCOG (UK), with over 15 years of specialist gynaecological experience, provides gynaecology-led HPV prevention consultations for women who want to discuss cervical cancer risk and prevention comprehensively
The best time to vaccinate against HPV is before any exposure. The second-best time is now. Do not wait for a health crisis to prompt this straightforward cancer-prevention step.
Chat with our medical assistant for quick guidance and support.
